A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies

NCT06971523 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

224

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Lymphoma

Interventions

DRUG: CTS3497

Sponsor

CytosinLab Therapeutics Co., Ltd.